v3.26.3
Collaborative, Licensing and Other Arrangements - Schedule of Recognized Revenue (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Other Revenue        
Other Revenue $ 1,889,815 $ 1,412,284 $ 5,108,324 $ 3,844,863
Other Revenue        
Other Revenue        
Other Revenue 34,758 17,271 86,144 39,244
Other Revenue | Novartis        
Other Revenue        
Other Revenue 34,758 17,271 86,144 39,244
Amgen royalty revenue | Novartis        
Other Revenue        
Other Revenue 25,744 12,169 62,864 26,721
Novartis broad markets revenue | Novartis        
Other Revenue        
Other Revenue 6,869 4,115 17,088 10,957
Other | Novartis        
Other Revenue        
Other Revenue $ 2,145 $ 987 $ 6,192 $ 1,566